Immunohistochemical Expression of Glutathione S‐Transferase π (GST‐π) and Chemotherapy Response in Malignant Ovarian Tumors

Hirazono, Kenichi; Shinozuka, Takao; Kuroshima, Yoshio; Kawai, Kenji

doi:10.1111/j.1447-0756.1995.tb01015.x

Cited by 21 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Table 3, we summarized published studies in which GSTP1-1 was determined in ovarian cancer tissue and related to the clinical outcomes of patients with EOC. Some researchers found a relationship between overexpression of GSTP1-1 in malignant ovarian tissue and poor prognosis or bad response to chemotherapy (8)(9)(10)(11)(12)(13), whereas others could not detect such an association (14)(15)(16)(17)(18)(19)(20)(21). These conflicting results might be explained by differences in techniques used to quantify GSTP1-1 (Table 3).…”

Section: Discussionmentioning

confidence: 99%

GSTP1-1 in Ovarian Cyst Fluid and Disease Outcome of Patients With Ovarian Cancer

Kolwijck

Zusterzeel

Roelofs

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Detoxification enzymes, especially glutathione S-transferase P1-1 (GSTP1-1), have been implicated in resistance to platinum-based chemotherapy. We studied GSTP1-1 levels in ovarian cyst fluid (oCF), obtained during surgery before chemotherapy, of patients with epithelial ovarian cancer and clinical outcomes were correlated. GSTP1-1 was determined by ELISA in oCF of 56 patients with epithelial ovarian cancer and 109 noncancer controls (21 borderline and 88 benign ovarian tumors). Differences in median GSTP1-1 between clinicopathologic subgroups were studied using Mann-Whitney U and Kruskal Wallis tests. Differences in disease-free (DFS) and overall survival (OS) between groups were analyzed by applying Kaplan-Meyer estimates and log-rank tests. Univariate and multivariate analysis were done using Cox proportional hazard model. Significantly higher levels of GSTP1-1 were found in the oCF of malignant (median, 383; range, 10-32,695 ng/mL) compared with benign (median, 20; range, 0-1,128 ng/mL) ovarian tumors (P < 0.01). Significantly higher GSTP1-1 levels were found in patients with advanced International Federation of Gynaecologists and Obstetricians stage (P = 0.01), high-grade tumors (P = 0.44), and/or high levels of preoperative CA 125 (P = 0.01). Of patients who received chemotherapy (stage, ≥Ic; n = 30), high GSTP1-1 levels were significantly associated with a poor DFS and OS (log-rank P = 0.047 and P = 0.033, respectively). International Federation of Gynaecologists and Obstetricians stage was the only independent predictor for DFS. GSTP1-1 was the only independent predictor for OS. (Cancer Epidemiol Biomarkers Prev 2009;18(8):2176-81)

show abstract

Section: Discussionmentioning

confidence: 99%

GSTP1-1 in Ovarian Cyst Fluid and Disease Outcome of Patients With Ovarian Cancer

Kolwijck

Zusterzeel

Roelofs

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…As a protein tag, GST is also a member of the GST gene fusion expression system, and therefore, is widely used in molecular immunology [4] , vaccine production [5,6] and study of protein-protein interactions [7] or protein-gene interactions [8] . It was reported that a certain type of GST was a potential drug target in treatment of multidrug resistant tumors [9,10] . Therefore, to prepare electrospun fibers capable of capturing GST is of both theoretical and practical significance in the field of protein science and materials, because they can be used not only for separation, enrichment and purification of GST itself, but also for separation and purification of all GST-tagged fused proteins.…”

Section: Introductionmentioning

confidence: 99%

PLLA-PCys co-electrospun fibers for capture and elution of glutathione S-transferase

Sun

Dong

et al. 2009

Sci. China Ser. B-Chem.

View full text Add to dashboard Cite

The copolymer poly(L-lactic acid)-b-poly(L-cysteine) (PLA-b-PCys) was co-electrospun with PLGA into ultrafine fibers. The reduced glutathione (GSH) was conjugated to the fiber surfaces via disulfide bonds. The glutathione S-transferase (GST) was captured onto the GSH fibers via specific substrate-enzyme interaction between the bound GSH and GST. The captured GST was eluted with free GSH aqueous solution and lyophilized to get pure GST powders. The results show that the GSH moieties on the fiber surface retain the bioactivity of the free GSH and thus they can bind specifically with GST and the GST in solution is captured onto the fiber surface. In addition, the bound GSH is not as active as free GSH so that the captured GST can be eluted off from the fiber by free GSH aqueous solution. Based on this principle, GST itself or its fused proteins can be separated and purified very easily. The preliminary purification efficiency is 6.5 mg⋅(g PCys ) −1 . Further improvements are undertaken. electrospun fibers, glutathione, glutathione S-transferase, protein separation and purification

show abstract

“…This enzyme is often increased in malignant tissues, irrespective of prior chemotherapy, and is suggested to serve as a multidrug-resistant factor in both inherent and acquired fashions (19,25,26). In fact, there are recent reports that disclosed a correlation between glutathione S-transferase P1-1 (GSTP1-1) expression in tumor tissues and the prognosis in ovarian cancer as well as in head and neck cancer (27,28).…”

Section: Introductionmentioning

confidence: 99%

Plasma Glutathione S -Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin’s Lymphoma (Stages III and IV)

Katahira

Takayama²,

Miyanishi³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: This study aims to investigate whether the plasma level of glutathione S-transferase P1-1 (GSTP1-1), which is a phase II detoxifying enzyme known to be a resistance factor for anticancer drugs, could be a prognostic factor of de novo non-Hodgkin lymphoma (NHL) in clinical stages (CSs) III and IV.Experimental Design: Study population consisted of 80 NHL patients with no prior treatment: 12 patients were at CS I, 14 at CS II, 25 at CS III, and 29 at CS IV. All 54 patients at CS III or CS IV were treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). Plasma GSTP1-1 concentration was measured by ELISA. We stained lymph node tissues for GSTP1-1 using anti-GSTP1-1 monoclonal antibody 5F and quantitatively assessed the intensity of immunostaining by using the KS-400 image analyzing system.Results: There was a significant stepwise increment of plasma GSTP1-1 concentration from CS I to CS IV (P < 0.05). Of the 54 patients with CS III or IV treated with CHOP, 28 (52%) had elevated plasma GSTP1-1 levels. Plasma GSTP1-1 concentration tended to correlate with the intensity of GSTP1-1 expression in lymphoma tissues as assessed by immunostaining (P ‫؍‬ 0.07). The CR rates in patients at CS III and CS IV treated by CHOP, 55.2% (14 of 26) and 16.0% (5 of 28) for the low and high plasma GSTP1-1 groups, respectively, were significantly different (P < 0.01). For these two groups, the median survival times were 64 and 25 months, respectively (P < 0.01), and the median times to progression were 58 and 12 months, respectively (P < 0.01). There was no significant correlation between plasma GSTP1-1 concentrations and other NHL prognostic indicators in these patients as determined by univariate and multivariate analyses.Conclusion: These results showed that plasma GSTP1-1 is a useful prognostic factor for CS III and IV advanced NHL. Thus, it may be a promising strategy to treat NHL concomitantly with anticancer drugs and GSTP1-1-specific inhibitors.

show abstract

Immunohistochemical Expression of Glutathione S‐Transferase π (GST‐π) and Chemotherapy Response in Malignant Ovarian Tumors

Abstract: Analysis of GST-pi obtained at primary surgery can serve as a valid marker in anticipating chemotherapeutic effects and long-term prognoses.

Cited by 21 publications

References 11 publications

GSTP1-1 in Ovarian Cyst Fluid and Disease Outcome of Patients With Ovarian Cancer

GSTP1-1 in Ovarian Cyst Fluid and Disease Outcome of Patients With Ovarian Cancer

PLLA-PCys co-electrospun fibers for capture and elution of glutathione S-transferase

Plasma Glutathione S -Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin’s Lymphoma (Stages III and IV)

Contact Info

Product

Resources

About